Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public offering nets $40.4mm for Sunesis

Executive Summary

Oncology drug developer Sunesis Pharmaceuticals Inc. netted $40.4mm through the public sale of 4.65mm common shares at $9.25. Investors also received warrants to purchase 9.3mm shares, with each buyer getting one common share, a Series A warrant for one share, and a Series B warrant for one share. The warrants carry the following terms: Series A warrants are exercisable at $8.50 and expire on the later of 30 calendar days after the unblinding date or December 4, 2014 (but in any event no later than March 4, 2016) of Phase III trial data for vosaroxin in combination with cytarabine for relapsed/refractory acute myeloid leukemia, and Series B warrants are exercisable at $12.00 and expire on the later of 30 calendar days after the PDUFA date for vosaroxin (but in any event no later than March 4, 2016) or September 4, 2015.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register